Form 4: Centessa Pharma Exec Sells Shares Under 10b5-1 Plan

Centessa Pharmaceuticals plc President, Orexin Program, Mario Alberto Accardi, sold 8,172 ordinary shares on September 16, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Mario Alberto Accardi, President of the Orexin Program at Centessa Pharmaceuticals plc, reported sales of ordinary shares.
• The transactions occurred on September 16, 2025.
• A total of 7,430 ordinary shares were sold at a weighted average price of $21.3333 per share, with prices ranging from $20.97 to $21.95.
• An additional 742 ordinary shares were sold at a weighted average price of $22.0213 per share, with prices ranging from $22.01 to $22.06.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted on February 14, 2025.
• Following these transactions, Accardi beneficially owns 197,394 ordinary shares.

Sentiment

Score: 4

Explanation: The filing reports an insider sale of shares by a key executive. While insider sales can sometimes be viewed negatively, the transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were not based on new, non-public information. This mitigates the potential negative sentiment, making it a neutral to slightly negative event.

Negatives

• An insider, Mario Alberto Accardi, President of the Orexin Program, sold a total of 8,172 ordinary shares.
• Insider sales can sometimes be perceived negatively by the market, suggesting a desire to diversify holdings or a lack of confidence, though mitigated by the 10b5-1 plan.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: May perceive the insider sale as a slight negative signal, though mitigated by the 10b5-1 plan, which indicates the sales were pre-scheduled and not based on immediate non-public information.

Key Dates

Recommendation

The filing details an insider sale by a key executive under a pre-arranged 10b5-1 trading plan. While insider sales can sometimes be a bearish signal, the existence of a 10b5-1 plan indicates the decision to sell was made in advance and not based on immediate, non-public information. This mitigates the negative impact. Without additional financial or operational news, this single transaction is unlikely to fundamentally alter the investment thesis for Centessa Pharmaceuticals plc, thus a 'hold' recommendation is appropriate, pending further developments.

Keywords

Centessa Pharmaceuticals, CNTA, Insider Trading, Form 4, Share Sale, Mario Alberto Accardi, 10b5-1 Plan, Orexin Program